United Therapeutics
UTHR
349 hedge funds and large institutions have $5.12B invested in United Therapeutics in 2020 Q2 according to their latest regulatory filings, with 87 funds opening new positions, 106 increasing their positions, 107 reducing their positions, and 38 closing their positions.
129% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 38
34% more call options, than puts
Call options by funds: $19.8M | Put options by funds: $14.8M
25% more capital invested
Capital invested by funds: $4.08B → $5.12B (+$1.04B)
15% more funds holding
Funds holding: 303 → 349 (+46)
1% less repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 107
1.81% less ownership
Funds ownership: 98.11% → 96.3% (-1.8%)
31% less funds holding in top 10
Funds holding in top 10: 13 → 9 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$61M |
| 2 |
Robeco Institutional Asset Management
Rotterdam,
Netherlands
|
+$57.3M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$47.3M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$42.2M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$32.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$128M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$59.1M |
| 3 |
State Street
Boston,
Massachusetts
|
-$45.3M |
| 4 |
Millennium Management
New York
|
-$44.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$34.9M |
UTHR Hedge Fund Activity: Q2 2020 in Review
349 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q2 2020, worth a combined $5.12B — up 25% from $4.08B a quarter earlier.
Buyers outnumbered sellers: 87 funds opened new UTHR positions and 38 closed out — a net gain of 49 holders — while 106 added to existing stakes and 107 trimmed.
The largest buyer was Invesco, adding an estimated $61M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $128M sold.
- 349 institutional investors held United Therapeutics (UTHR) as of Q2 2020, up from 303 in Q1 2020.
- Funds reported $5.12B of United Therapeutics stock for Q2 2020, up 25% quarter-over-quarter.
- 87 funds opened new United Therapeutics positions in Q2 2020 and 38 closed out, a net change of +49 holders.
- The largest United Therapeutics buyer in Q2 2020 was Invesco, an estimated $61M added.
- The largest United Therapeutics seller in Q2 2020 was Consonance Capital Management, an estimated $128M sold.
Based on aggregated 13F filings for Q2 2020.